4.7 Article

Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality

期刊

BLOOD
卷 122, 期 17, 页码 3062-3073

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-05-500801

关键词

-

资金

  1. National Institutes of Health Research Program [P01]
  2. National Institute of Allergy and Infectious Diseases [AI056299]
  3. Institute of Allergy and Infectious Diseases [AI034495]
  4. Heart, Lung and Blood Institute [HL056067, HL049997]
  5. National Cancer Institute [CA072669]
  6. National Center for Research Resources Shared Instrumentation Grant [1 S10 RR16851]
  7. Grants-in-Aid for Scientific Research [23249082] Funding Source: KAKEN

向作者/读者索取更多资源

Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, play an important role in the maintenance of peripheral tolerance. We explored the role of PD-1 ligands in regulating graft-versus-host disease (GVHD). Both PD-L1 and PD-L2 expression were upregulated in the spleen, liver, colon, and ileum of GVHD mice. Whereas PD-L2 expression was limited to hematopoietic cells, hematopoietic and endothelial cells expressed PD-L1. PD-1/PD-L1, but not PD-1/PD-L2, blockade markedly accelerated GVHD-induced lethality. Chimera studies suggest that PD-L1 expression on host parenchymal cells is more critical than hematopoietic cells in regulating acute GVHD. Rapid mortality onset in PD-L1-deficient hosts was associated with increased gut T-cell homing and loss of intestinal epithelial integrity, along with increased donor T-cell proliferation, activation, Th1 cytokine production, and reduced apoptosis. Bioenergetics profile analysis of proliferating alloreactive donor T-cells demonstrated increased aerobic glycolysis and oxidative phosphorylation in PD-L1-deficient hosts. Donor T-cells exhibited a hyperpolarized mitochondrial membrane potential, increased superoxide production, and increased expression of a glucose transporter in PD-L1-deficient hosts. Taken together, these data provide new insight into the differential roles of host PD-L1 and PD-L2 and their associated cellular and metabolic mechanisms controlling acute GVHD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medicine, Research & Experimental

Distinct myeloid antigen-presenting cells dictate differential fates of tumor-specific CD8+ T cells in pancreatic cancer

Adam L. Burrack, Zoe C. Schmiechen, Michael T. Patterson, Ebony A. Miller, Ellen J. Spartz, Meagan R. Rollins, Jackson F. Raynor, Jason S. Mitchell, Tsuneyasu Kaisho, Brian T. Fife, Ingunn M. Stromnes

Summary: We investigated the differential impact of myeloid subsets on immunity to pancreatic ductal adenocarcinoma (PDA). Our study demonstrates that tumor antigenicity shapes the composition and functionality of myeloid cells. The therapeutic effectiveness of adoptive T cell therapy or programmed cell death ligand 1 blockade relies on the presence of type 1 dendritic cells (cDC1), which support the survival and function of antitumor T cells. Our research highlights the essential role of cDC1s in sustaining effective antitumor T cells and reveals differential roles for cDC1s and monocytes/macrophages in guiding T cell fate and immunotherapy response.

JCI INSIGHT (2022)

Article Multidisciplinary Sciences

PD-1 blockade following ART interruption enhances control of pathogenic SIV in rhesus macaques

Vijayakumar Velu, Kehmia Titanji, Hasan Ahmed, Ravi Dyavar Shetty, Lakshmi S. Chennareddi, Gordon J. Freeman, Rafi Ahmed, Rama Rao Amara

Summary: The study demonstrated that PD-1 blockade following ART interruption significantly enhances the function of anti-viral CD8 T cells and improves viral control. It suggests the potential synergistic effects of PD-1 blockade with other immunotherapies inducing functional CD8 T-cell responses.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Correction Immunology

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (vol 49, 1148.e1, 2018)

Christopher S. Garris, Sean P. Arlauckas, Rainer H. Kohler, Marcel P. Trefny, Seth Garren, Cecile Piot, Camilla Engblom, Christina Pfirschke, Marie Siwicki, Jeremy Gungabeesoon, Gordon J. Freeman, Sarah E. Warren, SuFey Ong, Erica Browning, Christopher G. Twitty, Robert H. Pierce, Mai H. Le, Alain P. Algazi, Adil I. Daud, Sara I. Pai, Alfred Zippelius, Ralph Weissleder, Mikael J. Pittet

IMMUNITY (2022)

Article Multidisciplinary Sciences

PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program

Masao Hashimoto, Koichi Araki, Maria A. Cardenas, Peng Li, Rohit R. Jadhav, Haydn T. Kissick, William H. Hudson, Donald J. McGuire, Rebecca C. Obeng, Andreas Wieland, Judong Lee, Daniel T. McManus, James L. Ross, Se Jin Im, Junghwa Lee, Jian-Xin Lin, Bin Hu, Erin E. West, Christopher D. Scharer, Gordon J. Freeman, Arlene H. Sharpe, Suresh S. Ramalingam, Alex Pellerin, Volker Teichgraber, William J. Greenleaf, Christian Klein, Jorg J. Goronzy, Pablo Umana, Warren J. Leonard, Kendall A. Smith, Rafi Ahmed

Summary: The study showed that combination therapy with PD-1 blockade and IL-2 during chronic lymphocytic choriomeningitis virus infection significantly alters the differentiation program of CD8(+) T cells, resulting in the generation of highly functional effector CD8(+) T cells that mediate viral control, thus providing a new perspective for cancer treatment.

NATURE (2022)

Article Medicine, General & Internal

Immune checkpoint expression on HIV-specific CD4+ T cells and response to their blockade are dependent on lineage and function

Elsa Brunet-Ratnasingham, Antigoni Morou, Mathieu Dube, Julia Niessl, Amy E. Baxter, Olivier Tastet, Nathalie Brassard, Gloria Ortega-Delgado, Roxanne Charlebois, Gordon J. Freeman, Cecile Tremblay, Jean-Pierre Routy, Daniel E. Kaufmann

Summary: This study examined the expression and function of immune checkpoints in CD4+ T cells of HIV-infected individuals and found that the expression of immune checkpoints is associated with infection status and effector profile. In addition, different subsets of CD4+ T cells show varying sensitivity to PD-1-mediated inhibition, suggesting heterogeneity in the restoration of cell function through immune checkpoint blockade.

EBIOMEDICINE (2022)

Meeting Abstract Hematology

Immuno-Genetic Changes Underlie Response to Immune Checkpoint Blockade Therapy in Richter's Syndrome Mouse Models

Elisa Ten Hacken, Gabriela Brunsting Hoffmann, Kayla Cruz, Erin Michelle Parry, Elizabeth Witten, Donna S. Neuberg, Gordon J. Freeman, Catherine J. Wu

Article Immunology

Immunoregulatory effects of RGMb in gut inflammation

Magdiel Perez-Cruz, Bettina P. Iliopoulou, Katie Hsu, Hsin-Hsu Wu, Tom Erkers, Kavya Swaminathan, Sai-Wen Tang, Cameron S. Bader, Neeraja Kambham, Bryan Xie, Rosemarie H. Dekruyff, Gordon J. Freeman, Everett Meyer

Summary: The study suggests that RGMb may play a role in the pathogenesis of GvHD and IBD. Treatment with an anti-RGMb monoclonal antibody in mouse models prevented GvHD and IBD, while maintaining the graft-versus-tumor effect. The findings highlight the potential of targeting RGMb as a therapeutic strategy for these conditions.

FRONTIERS IN IMMUNOLOGY (2022)

Article Oncology

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer

Liya Ding, Qiwei Wang, Antons Martincuks, Michael J. Kearns, Tao Jiang, Ziying Lin, Xin Cheng, Changli Qian, Shaozhen Xie, Hye-Jung Kim, Inga-Maria Launonen, Anniina Faerkkilae, Thomas M. Roberts, Gordon J. Freeman, Joyce F. Liu, Panagiotis A. Konstantinopoulos, Ursula Matulonis, Hua Yu, Jean J. Zhao

Summary: This study reveals an adaptive immunosuppression mechanism that leads to resistance to PARP inhibition in BRCA1-mutant ovarian tumors. This resistance is mediated by an increased population of protumor tumor-associated macrophages (TAMs) and activation of the STAT3 signaling pathway. The use of STING agonists can reshape the immunosuppressive tumor microenvironment and overcome PARPi resistance in ovarian cancer.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Article Oncology

Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment

John D. Klement, Priscilla S. Redd, Chunwan Lu, Alyssa D. Merting, Dakota B. Poschel, Dafeng Yang, Natasha M. Savage, Gang Zhou, David H. Munn, Padraic G. Fallon, Kebin Liu

Summary: This study found that tumor cell surface PD-L1 does not suppress cytotoxic T lymphocyte activity and has no effect on primary tumor growth. However, deletion of tumor cell surface PD-L1 decreases lung metastasis in a CTL-dependent manner. Depletion of myeloid cells or knocking out PD-1 in myeloid cells impairs PD-L1 promotion of tumor lung metastasis. Single-cell RNA sequencing revealed that PD-L1 engages myeloid cells PD-1 to activate SHP2 and repress the IFN-I-STAT1-CXCL9 pathway to impair CTL recruitment in lung metastasis.

CANCER CELL (2023)

Article Multidisciplinary Sciences

mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion

Heng-Jia Liu, Heng Du, Damir Khabibullin, Mahsa Zarei, Kevin Wei, Gordon J. Freeman, David J. Kwiatkowski, Elizabeth P. Henske

Summary: This study reveals that B7-H3 expression is correlated with immunosuppressive phenotypes and worse clinical outcomes in human tumors with high mTORC1 activity. The authors show that mTORC1 upregulates B7-H3 expression by phosphorylating the transcription factor YY2. Inhibiting B7-H3 enhances T-cell activity and induces tumor cell expression of MHC-II, suppressing tumor growth with mTORC1 hyperactivity.

NATURE COMMUNICATIONS (2023)

Article Multidisciplinary Sciences

PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity

Jing Liu, Xia Bu, Chen Chu, Xiaoming Dai, John M. Asara, Piotr Sicinski, Gordon J. Freeman, Wenyi Wei

Summary: The protein arginine methyltransferase PRMT1 suppresses the anti-tumor immune response by methylating cGAS and preventing its dimerization. Inhibition of PRMT1 activates the cGAS/STING-dependent DNA sensing signaling and increases the expression of interferon response genes, tumor-infiltrating lymphocytes, and tumoral PD-L1. Combination therapy of PRMT1 inhibitor with anti-PD-1 antibody enhances the anti-tumor therapeutic efficacy.

NATURE COMMUNICATIONS (2023)

Article Medicine, Research & Experimental

mTOR regulates T cell exhaustion and PD-1-targeted immunotherapy response during chronic viral infection

Satomi Ando, Charles M. Perkins, Yamato Sajiki, Chase Chastain, Rajesh M. Valanparambil, Andreas Wieland, William H. Hudson, Masao Hashimoto, Suresh S. Ramalingam, Gordon J. Freeman, Rafi Ahmed, Koichi Araki

Summary: T cell exhaustion is associated with dysfunction and expression of PD-1. mTOR inhibition during the expansion phase enhances T cell response, while inhibition after exhaustion progresses causes immunosuppression with decreased TIM3(+) cells and increased viral load. mTOR signaling is essential for differentiation of stem-like T cells into TIM3(+) cells.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Article Medicine, Research & Experimental

Tregs with an MHC class II peptide-specific chimeric antigen receptor prevent autoimmune diabetes in mice

Justin A. Spanier, Vivian Fung, Christine M. Wardell, Mohannad H. Alkhatib, Yixin Chen, Linnea A. Swanson, Alexander J. Dwyer, Matthew E. Weno, Nubia Silva, Jason S. Mitchell, Paul C. Orban, Majid Mojibian, C. Bruce Verchere, Brian T. Fife, Megan K. Levings

Summary: Engineering Tregs with specific recognition for islet antigens using a chimeric antigen receptor (CAR) is a promising therapeutic approach for preventing autoimmune diabetes.

JOURNAL OF CLINICAL INVESTIGATION (2023)

Meeting Abstract Immunology

A comparison of monoclonal antibodies against murine PD-1 and PD-L1

Melissa Tian Bu, Long Yuan, Alyssa Klee, Gordon J. Freeman

JOURNAL OF IMMUNOLOGY (2022)

Article Gastroenterology & Hepatology

Type 1 Diabetes in Acute Pancreatitis Consortium From Concept to Reality

Jose Serrano, Maren R. Laughlin, Melena D. Bellin, Dhiraj Yadav, Vernon M. Chinchilli, Dana K. Andersen

Summary: Acute pancreatitis (AP) is inflammation of the pancreas and accounts for over 300,000 US hospital discharges annually. Recent studies have found that 30% to 40% of AP patients develop diabetes or impaired glucose tolerance within 3 to 4 years after a single episode of AP. To investigate the association between AP and type 1 diabetes, the National Institute of Diabetes and Digestive and Kidney Diseases funded the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC), which conducted a prospective observational study.

PANCREAS (2022)

暂无数据